National OncoVenture
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://nov.ncc.re.kr
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- National OncoVenture
- Target Recruit Count
- 30
- Registration Number
- NCT02300467
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
- Conditions
- Adenocarcinoma of Lung Stage IVAdenocarcinoma of Lung Stage IIIB
- Interventions
- Drug: NOV120101 (Poziotinib)
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- National OncoVenture
- Target Recruit Count
- 22
- Registration Number
- NCT01819428
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Gachon University Gil Hospital, Namdong-Gu, Incheon,, Korea, Republic of
🇰🇷Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of
NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
- Conditions
- Increased Drug Resistance
- Interventions
- Drug: NOV120101 (Poziotinib)
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- National OncoVenture
- Target Recruit Count
- 40
- Registration Number
- NCT01718847
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si,, Chungcheongbuk-do, Korea, Republic of
🇰🇷National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of